

Indications:

• Chronic, STABLE pain requiring around-the-clock opioid relief in patients that are **opioid tolerant** (taking at least 60 mg/day of oral morphine equivalent for 7 days or longer).

Contradictions:

- NOT appropriate for mild, unstable, or uncontrolled pain.
 - Uncontrolled Pain is > 3 Breakthrough pain medication doses in a 24 hour period
- NOT appropriate in a patient experiencing a pain crisis.

Points to Consider:

- It is **strongly recommended** for all prescribers to utilize the Fentanyl Transdermal Patch order set for all fentanyl transdermal patch orders.
- Always include appropriate immediate release breakthrough analgesia as suggested on the Fentanyl Transdermal Patch order set.
- You can find the <u>Fentanyl Transdermal Patch (10-111-5338)</u> order set on DocumentSource.
- For additional support, particularly if rotating on or off of the fentanyl patch, please contact the NH Palliative Care Consultation Team at 250-645-3791 or Palliative.Care.Consult.Team@northernhealth.ca



Fig. 4.4 2 1000 to		s darm s									
Fig. 4.4 2 1000 to	Allergies: No	entanyi Transdermai Patch									
					Page 2	\$16					
December Proceedings Process			☐ Unabi	to obtain							
### 1970	Table 1. feetaWfL t	ranoderma)	patch equiasa	igesis cones	mion ¹⁷						
Separation of the Control of the Con	Oral exceptions	Subi	VER-JOHNSTIG			Subouts	recusily	ONE REVCODOR	E. Transferred feetaWY		
### 17 17 17 17 17 17 17 1	(mg per day)							(mg per day)	(weg per heur)		
### 15 10 10 10 10 10 10 10	63 to 134 mg			174	er day)			45 to \$9 mg	Street		
10 10 10 10 10 10 10 10	135 to 177 min			12 m	20 mg	16.00	11 00	90 to 119 mg			
10 10 10 10 10 10 10 10	130 to 179 mg 160 to 234 mg					12 to	22 mg				
18 to 15 t								150 to 179 mg			
with the SEC of the SE	270 to 314 mg	135	to 107 mg	54.50	55.70	27 to	31 mg	160 to 200 mg	75 mag		
2016 1974 11 10 20 20 41 14 14 16 77(1) 2 2016 1974 11 10 20 20 41 14 16 77(1) 2 2016 1974 10 17 10 20 20 41 14 16 77(1) 2 2016 1974 10 17 17 20 17 17 20 17 17 20 17 17 2016 1974 10 17 17 20 17 17 20 17 17 20 17 17 2016 1974 10 17 17 20 17 17 20 17 17 2016 1974 10 17 17 20 17 17 20 17 17 2016 1974 10 17 17 20 17 17 2016 1974 10 17 17 20 17 17 2016 1974 10 17 17 20 17 17 2017 10 17 17 20 17 17 201	315 to 359 mg 360 to 404 mg	150	e to 119 mg	63 to	r1 mg	22 10	xo mg	210 to 239 mg 240 to 219 mg	87 mag 190 mag		
200 to 10 to	405 to 404 mg	100	1 to 202 mg	77.40	50 mg	31 to	40 mg	240 to 299 mg	190 mag 112 mag		
2-dis 20-dis 30-dis 30 reg. 20 to 50 reg. 20 to 10 reg. 20	450 to 424 mg	29	5 to 247 ma	90 to	98 ma	45.90	tic mo	300 to 329 mg	125 mag		
of one-COOPE commences are based on a management in FIREDERORAPHEM resident and of the contract from the contract of the contract from the contract of the con	495 to 539 mg	241	to 209 mg	99 to	107 mg	52 to	53 mg	330 to 359 mg	137 mag		
of one-COOPE commences are based on a management in FIREDERORAPHEM resident and of the contract from the contract of the contract from the contract of the con	540 to 584 mg	271	1 to 292 mg	150 %	118 mg	54 to	56 mg	350 to 322 mg	150 mag		
5 mg 2.5 mg 1 mg 0.5 m									cayCODONE		
10g 23ng 1ng 33n				25.04				Subodateous	Oral inmediate release 2.5 mg		
	15 may per hour			1 mg		2 mg			2.000		
15 mg 7.5 mg 1.5 mg	37 Weig per hour	15 mg			9	3 mg		15.00	5 mg 10 mg		
20 mg 10 mg 4 mg 2 mg	50 mag per hour	20 mg		10 mg		4 mg		2 mg :	12.5 mg		
	\$2 mag per hour								15 mg		
	75 mag per hour			12.5 ing		5 mg		2.5 mg	17.5 mg		
	ET mag per hour	30 mg		15 reg				3 mg	20 mg		
35 mg 15 mg 5 mg 3 mg									25 mg		
30 mg 15 mg 5 mg 3 mg 30 mg 17.5 mg 7 mg 3.5 m			itiation of feet	MYL transde	erinal parish.	and dissorts	reastion of g	eier opioids*			
50 mg 15 mg 6 mg 3 mg 30 mg 17.5 mg 7 mg 3.5 m for initiation of femal(Y), transitiental gates and discontinuation of griss opinish?		From other opioid to fentaWYL transformal (FTD) parch		Shour		Ahour		£ hour	12 hour		
20 mg 15 mg 6 mg 3 mg 25 mg 3 mg 3.5 mg 3	From other opioid to transformal (FT			remediate reliance dates		release dose					
20 mg 15 mg 6 mg 3 mg 5 mg 3 mg 5 mg 15 mg 1	From other opioid to intercolormal (FT Oral immediate in transformal)	elema to patch	remediate n	hone free		e down	minane	dose fren stop	No immediate relicate dos		
25 mg 15 mg 6 mg 7 mg 3.5 mg	From other opioid to transformal (FT Cral immediate in	elease to patch ase to FTD	Apply patch sustained to	none free - gue one lease sone	No sustain do	e dose ed release se	No sasta	ned release dose	No immediate religion dos No sustained religion dos		
15 mg 20 mg 25 mg 25 mg	feetaNYL patch strength 12 mag per hour 25 mag per hour 37 mag per hour 50 mag per hour	Oral invine 11 12 23 24 20 30 30 adular for ini	date not req req req req req req req	ease ease of feet	New Subscise			MYSSB0000 MYSSB0000	International Continues International Co		
	ser hour					5 mg		2.5 mg	15 mg		
	12 mag per hour	25 mg		12.0 (0)		5 mg		2.5 Fig.	17.5-mg		
	ET mag per hour	50 mg		15 mg				3 mg	25 mg		
	tr mag per hour	20.69		10.100				2 86	20 mg		
	100 may per hour	W-re		17.6 mm				28.00	20 mg		
Ming Ming Sing Sing	100 mod per hour	35 mg		17.5 mg				3.5 mg	25 mg		
35 mg 15 mg 5 mg 3 mg	Too mog per hour								25 mg		
35 mg 15 mg 5 mg 3 mg		redule for in	ationius of feet	MYL transde	ermal partch	and discenti	realtion of p	rior opinids)			
30 mg 15 mg 5 mg 3 mg 30 mg 17.5 mg 7 mg 3.5 m	Tobie 3. Switch salt	feetaWYL					-		12 hour		
35 mg 15 mg 6 mg 3 mg 35 mg 17.5 mg 7 mg 3.5 m for initiation of feetalW1, transdomnal patch and discontinuation of prior opioids ¹ W1.	From other opioid to						One lest requier immediate		10000		
20 mg 15 mg 6 mg 3 mg 25 mg 3 mg 3.5 mg 3	From other opioid to transformal (FT				release done						
20 mg 15 mg 6 mg 3 mg 5 mg 3 mg 5 mg 15 mg 1	From other opioid to intercolormal (FT Crall immediate in transformal)	elema to patch	remediate n	hone free		e down	release	dose fren slop	No immediate religion dos		
20 mg 15 mg 6 mg 7 mg 20 mg 20 mg 21 mg 21 mg 21 mg 24 mg	From other oproid to transdomial (FT Cral immediate in transdomial) Cral sustained rele	elema to patch	Apply patch	none free	No sustain	e dose ed release		again to the page			

More information on the use of the fentanyl transdermal patch in palliative patients can be found in the <u>NH Palliative Care Program Symptom Guidelines 4th Edition</u> under the chapter, "Principles of Opioid Management."

